ArticleMolecular psychiatry2026
Differential protein network and biological functions atlas from multi-tissue proteomics in patients with depression.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression leads to complex changes in protein regulation in the brain and other tissues. Reproducibility and data integration remain challenges in this field. We systematically integrated proteomic data from our previous established database Pro-MENDA, encompassing brain, cerebrospinal fluid (CSF), blood, and urine samples from patients with depression. Using a vote-counting statistics to assess consistency of protein expression changes across studies, we identified 2094 different expression proteins from 1804 samples. Functional characterization included Gene Ontology, KEGG pathway enrichment, protein-protein interaction analysis, and post-translational modification. In brain, we observed changes in proteins related to synaptic function and energy metabolism, such as Glial fibrillary acidic protein (GFAP) and Histidine triad nucleotide-binding protein 1 (HINT1). These changes suggest issues with oxidative phosphorylation and synaptic activity. The CSF and blood revealed immune-inflammatory markers like Afamin (AFM) and Serpin Family F Member 1 (SERPINF1), while urine analysis showed signs of neutrophil activation. We also identified 13 shared proteins across brain, CSF, and blood, including Clusterin (CLU), that link complement and coagulation, and reactive oxygen pathways. In this protein-protein interaction network of brain, proteins related to cell adhesion, respiration, neuron and synapse are significantly enriched. Post-translational modifications, particularly phosphorylation, were common. Our findings highlight systemic protein dysregulation in depression. This connects brain and peripheral mechanisms, offering insights for identifying multi-tissue biomarkers and developing targeted therapies.
Indexed as
Identifiers
41611983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.